Catharina Johansson appointed new CFO, effective 1 December

NeuroVive Pharmaceutical AB (publ), a leading mitochondrial medicine company,
has appointed Catharina Johansson as the company’s new CFO. She will take up her
position on 1 December. This appointment concludes the recruitment process
initiated earlier this year when the company’s previous CFO, Christian Svensson,
announced his decision to step down, to focus on his own consulting practice.
Catharina Johansson was formerly Interim CFO of medical technology company
Cellavision, listed on NASDAQ OMX Stockholm, as well as Head of Accounting at
Bong and Alfa Laval Europe. She holds an M.Sc. in Business and Economics and is
based in Lund, Sweden where NeuroVive’s headquarters are located.

Mikael Brönnegård, CEO of NeuroVive Pharmaceutical AB, said: “Catharina
Johansson’s experience from a listed medical technology growth company with
international operations means she’s well prepared for the role as CFO of
NeuroVive. I’m certain that her experience and drive will be a great asset to
NeuroVive when we develop our position as a leader with many international
collaborations and revenue sources.”

Catharina Johansson, the new CFO of NeuroVive Pharmaceutical AB, said:
“NeuroVive is right in a really interesting development phase, and I look
forward to using my experience of similar positions to help move the company
forward. I prefer dynamic companies that present constant challenges, so I
expect to fit well into NeuroVive’s development-driven business operations.”

NeuroVive’s former CFO Christian Svensson will continue to serve the company on
a consultancy basis until Catharina takes up her new position, and during a
transitional phase. Accordingly, the transition is expected to be smooth, with
no effect on day-to-day business.

About NeuroVive
NeuroVive Pharmaceutical AB, a leading mitochondrial medicine company, is
developing a portfolio of products to treat acute cardiovascular and
neurological conditions through mitochondrial protection. These medical
conditions are characterized by a pressing medicinal need and have no approved
pharmaceutical treatment options at present. NeuroVive’s products CicloMulsion®
(heart attack) and NeuroSTAT® (traumatic brain injury) are currently being
evaluated in phase III and phase II studies, respectively. NeuroVive’s research
programs also include products for the treatment of anti-viral indications
(Hepatitis B/C), brain cell injury in stroke patients, and drug candidates for
cellular protection and treating mitochondria-related energy regulation
diseases. NeuroVive’s shares are listed on NASDAQ OMX, Stockholm, Sweden.

Media and investor relations contact:
Ingmar Rentzhog, Laika Consulting, tel: +46 (0)46 275 6221, email:
ir@neurovive.com

Please also use the above contact if you wish to arrange an interview with
NeuroVive’s CEO, Mikael Brönnegård.

NeuroVive Pharmaceutical AB (publ)
Medicon Village, SE-223 81 Lund, Sweden, tel: +46 (0)46 275 6220 (switchboard),
Fax: +46 (0)46 888 8348, info@neurovive.com, www.neurovive.com

NeuroVive Pharmaceutical AB (publ) is obligated to publish the information
contained in this press release in accordance with the Swedish Securities Market
Act. This information was provided to the media for publication at 08:00 a.m.
CEST on October 9, 2013.